Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer
Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in adv...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yamaguchi, Toshifumi [verfasserIn] Iwasa, Satoru [verfasserIn] Shoji, Hirokazu [verfasserIn] Honma, Yoshitaka [verfasserIn] Takashima, Atsuo [verfasserIn] Kato, Ken [verfasserIn] Hamaguchi, Tetsuya [verfasserIn] Higuchi, Kazuhide [verfasserIn] Boku, Narikazu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 22(2019), 4 vom: 02. Jan., Seite 778-784 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2019 ; number:4 ; day:02 ; month:01 ; pages:778-784 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-018-00917-5 |
|---|
| Katalog-ID: |
SPR00935025X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR00935025X | ||
| 003 | DE-627 | ||
| 005 | 20230519193103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-018-00917-5 |2 doi | |
| 035 | |a (DE-627)SPR00935025X | ||
| 035 | |a (SPR)s10120-018-00917-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaguchi, Toshifumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. | ||
| 650 | 4 | |a Gastric cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a UGT1A1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Irinotecan |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Iwasa, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Shoji, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Honma, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Takashima, Atsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Hamaguchi, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Kazuhide |e verfasserin |4 aut | |
| 700 | 1 | |a Boku, Narikazu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 22(2019), 4 vom: 02. Jan., Seite 778-784 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2019 |g number:4 |g day:02 |g month:01 |g pages:778-784 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-018-00917-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2019 |e 4 |b 02 |c 01 |h 778-784 | ||
| author_variant |
t y ty s i si h s hs y h yh a t at k k kk t h th k h kh n b nb |
|---|---|
| matchkey_str |
yamaguchitoshifumiiwasasatorushojihiroka:2019----:soitobteng11eeoyopimnsftadfiayfrntcnoohrpatehrln |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1007/s10120-018-00917-5 doi (DE-627)SPR00935025X (SPR)s10120-018-00917-5-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 Iwasa, Satoru verfasserin aut Shoji, Hirokazu verfasserin aut Honma, Yoshitaka verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Higuchi, Kazuhide verfasserin aut Boku, Narikazu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 4 vom: 02. Jan., Seite 778-784 (DE-627)SPR009286586 nnns volume:22 year:2019 number:4 day:02 month:01 pages:778-784 https://dx.doi.org/10.1007/s10120-018-00917-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 22 2019 4 02 01 778-784 |
| spelling |
10.1007/s10120-018-00917-5 doi (DE-627)SPR00935025X (SPR)s10120-018-00917-5-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 Iwasa, Satoru verfasserin aut Shoji, Hirokazu verfasserin aut Honma, Yoshitaka verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Higuchi, Kazuhide verfasserin aut Boku, Narikazu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 4 vom: 02. Jan., Seite 778-784 (DE-627)SPR009286586 nnns volume:22 year:2019 number:4 day:02 month:01 pages:778-784 https://dx.doi.org/10.1007/s10120-018-00917-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 22 2019 4 02 01 778-784 |
| allfields_unstemmed |
10.1007/s10120-018-00917-5 doi (DE-627)SPR00935025X (SPR)s10120-018-00917-5-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 Iwasa, Satoru verfasserin aut Shoji, Hirokazu verfasserin aut Honma, Yoshitaka verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Higuchi, Kazuhide verfasserin aut Boku, Narikazu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 4 vom: 02. Jan., Seite 778-784 (DE-627)SPR009286586 nnns volume:22 year:2019 number:4 day:02 month:01 pages:778-784 https://dx.doi.org/10.1007/s10120-018-00917-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 22 2019 4 02 01 778-784 |
| allfieldsGer |
10.1007/s10120-018-00917-5 doi (DE-627)SPR00935025X (SPR)s10120-018-00917-5-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 Iwasa, Satoru verfasserin aut Shoji, Hirokazu verfasserin aut Honma, Yoshitaka verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Higuchi, Kazuhide verfasserin aut Boku, Narikazu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 4 vom: 02. Jan., Seite 778-784 (DE-627)SPR009286586 nnns volume:22 year:2019 number:4 day:02 month:01 pages:778-784 https://dx.doi.org/10.1007/s10120-018-00917-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 22 2019 4 02 01 778-784 |
| allfieldsSound |
10.1007/s10120-018-00917-5 doi (DE-627)SPR00935025X (SPR)s10120-018-00917-5-e DE-627 ger DE-627 rakwb eng Yamaguchi, Toshifumi verfasserin aut Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 Iwasa, Satoru verfasserin aut Shoji, Hirokazu verfasserin aut Honma, Yoshitaka verfasserin aut Takashima, Atsuo verfasserin aut Kato, Ken verfasserin aut Hamaguchi, Tetsuya verfasserin aut Higuchi, Kazuhide verfasserin aut Boku, Narikazu verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 4 vom: 02. Jan., Seite 778-784 (DE-627)SPR009286586 nnns volume:22 year:2019 number:4 day:02 month:01 pages:778-784 https://dx.doi.org/10.1007/s10120-018-00917-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 22 2019 4 02 01 778-784 |
| language |
English |
| source |
Enthalten in Gastric Cancer 22(2019), 4 vom: 02. Jan., Seite 778-784 volume:22 year:2019 number:4 day:02 month:01 pages:778-784 |
| sourceStr |
Enthalten in Gastric Cancer 22(2019), 4 vom: 02. Jan., Seite 778-784 volume:22 year:2019 number:4 day:02 month:01 pages:778-784 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Gastric cancer UGT1A1 Irinotecan |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Yamaguchi, Toshifumi @@aut@@ Iwasa, Satoru @@aut@@ Shoji, Hirokazu @@aut@@ Honma, Yoshitaka @@aut@@ Takashima, Atsuo @@aut@@ Kato, Ken @@aut@@ Hamaguchi, Tetsuya @@aut@@ Higuchi, Kazuhide @@aut@@ Boku, Narikazu @@aut@@ |
| publishDateDaySort_date |
2019-01-02T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR00935025X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR00935025X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193103.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-018-00917-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR00935025X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-018-00917-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamaguchi, Toshifumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">UGT1A1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Irinotecan</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iwasa, Satoru</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shoji, Hirokazu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Honma, Yoshitaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Ken</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Higuchi, Kazuhide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boku, Narikazu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2019), 4 vom: 02. Jan., Seite 778-784</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield><subfield code="g">day:02</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:778-784</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-018-00917-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield><subfield code="b">02</subfield><subfield code="c">01</subfield><subfield code="h">778-784</subfield></datafield></record></collection>
|
| author |
Yamaguchi, Toshifumi |
| spellingShingle |
Yamaguchi, Toshifumi misc Gastric cancer misc UGT1A1 misc Irinotecan Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| authorStr |
Yamaguchi, Toshifumi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer Gastric cancer (dpeaa)DE-He213 UGT1A1 (dpeaa)DE-He213 Irinotecan (dpeaa)DE-He213 |
| topic |
misc Gastric cancer misc UGT1A1 misc Irinotecan |
| topic_unstemmed |
misc Gastric cancer misc UGT1A1 misc Irinotecan |
| topic_browse |
misc Gastric cancer misc UGT1A1 misc Irinotecan |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| ctrlnum |
(DE-627)SPR00935025X (SPR)s10120-018-00917-5-e |
| title_full |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| author_sort |
Yamaguchi, Toshifumi |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
778 |
| author_browse |
Yamaguchi, Toshifumi Iwasa, Satoru Shoji, Hirokazu Honma, Yoshitaka Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Higuchi, Kazuhide Boku, Narikazu |
| container_volume |
22 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yamaguchi, Toshifumi |
| doi_str_mv |
10.1007/s10120-018-00917-5 |
| author2-role |
verfasserin |
| title_sort |
association between ugt1a1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| title_auth |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| abstract |
Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. |
| abstractGer |
Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. |
| abstract_unstemmed |
Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer |
| url |
https://dx.doi.org/10.1007/s10120-018-00917-5 |
| remote_bool |
true |
| author2 |
Iwasa, Satoru Shoji, Hirokazu Honma, Yoshitaka Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Higuchi, Kazuhide Boku, Narikazu |
| author2Str |
Iwasa, Satoru Shoji, Hirokazu Honma, Yoshitaka Takashima, Atsuo Kato, Ken Hamaguchi, Tetsuya Higuchi, Kazuhide Boku, Narikazu |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-018-00917-5 |
| up_date |
2024-07-04T01:41:43.296Z |
| _version_ |
1803610806863003648 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR00935025X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193103.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-018-00917-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR00935025X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-018-00917-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yamaguchi, Toshifumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified. Methods Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes. Results Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%). Conclusions The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">UGT1A1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Irinotecan</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iwasa, Satoru</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shoji, Hirokazu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Honma, Yoshitaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takashima, Atsuo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Ken</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Tetsuya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Higuchi, Kazuhide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boku, Narikazu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2019), 4 vom: 02. Jan., Seite 778-784</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield><subfield code="g">day:02</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:778-784</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-018-00917-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield><subfield code="b">02</subfield><subfield code="c">01</subfield><subfield code="h">778-784</subfield></datafield></record></collection>
|
| score |
7.401293 |